Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Ltd Technicals

Asston Pharmaceuticals Ltd Financials

Asston Pharmaceuticals Ltd Shareholding Pattern

About Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Limited was incorporated on 16th April 2019 as 'Asston Pharmaceutical Pvt. Limited' to contract produce pharmaceutical products for export market. Later on 1st April 2024, Company acquired Ferron Lifecare Private Limited, specializing into nutraceuticals business and produced nutraceutical products at their Ambarnath facility. Ferron Lifecare Private Limited, incorporated on 30th January 2020. Finally, 'Asston Pharmaceuticals Private Limited' was converted into a Public Limited Company in the name of 'Asston Pharmaceuticals Limited' on 29th August 2024 and received FDA approval for its Ambarnath facility on 2nd December 2024 to produce pharmaceutical products. Presently, Company is involved in the business of manufacturing and marketing of Tablets, Capsules, Oral Liquid, External Preparations (Ointment, Cream, Gel and Lotion) and Oral Powder (Sachet, Dry Syrup) etc. Company's operations are supported by experienced founders with expertise in managing supply chains and maintaining product quality. Currently, Company has its production plant at Ambernath, Maharashtra, for producing generic medicines in the tablet form and nutraceutical medicines in the tablet form, syrup and sachet form. Facility has total production capacity of up to around 8-9 crore tablets per month. Further, it produces an average of 5-6 crore tablets per month, with production capacity varying based on the weight of medicines. Higherweight medicines result in lower production ...quantities and vice versa. The syrup production capacity for nutraceuticals is approximately 37.5 kiloliters per month, while sachet production capacity ranges from 30 to 40 lakh sachets per month, depending on the powder weight per sachet. The facility is certified by relevant authorities and undergoes periodic audits by state and central FDA authorities. Company engages contract manufacturers to produce generic medicines and antibiotics in various forms, including tablets, sachets, syrups, and capsules. The Company has ventured into other African countries to receive registration from the Asian markets like Cambodia and Vietnam in FY 2024. Company came up with the IPO of 22,41,000 equity shares of Rs 10, by raising Rs 27.56 crore in July, 2025.

Similar Stocks